Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

NCT03355066 is registered in ClinicalTrials.gov with Biosplice Therapeutics, Inc. as lead sponsor.

NCT NCT03355066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03355066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Lead sponsor
Biosplice Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 6, 2017
Completion date
November 14, 2022
Enrollment
82 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult